Patents by Inventor Philippe Guerry

Philippe Guerry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11339148
    Abstract: The invention relates to crystalline forms of (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide; processes for the preparation thereof, pharmaceutical compositions containing such crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as CXCR7 receptor modulators.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: May 24, 2022
    Assignee: IDORSIA PHARMACEUTICALS LTD.
    Inventors: Philippe Guerry, Markus Von Raumer
  • Patent number: 11306078
    Abstract: The present invention relates to piperidine derivatives of formula (I) wherein Ar1, Ar2, RAr1, R1, R2, and R3 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: April 19, 2022
    Assignee: IDORSIA PHARMACEUTICALS LTD.
    Inventors: Hamed Aissaoui, Philippe Guerry, Francois Lehembre, Julien Pothier, Laetitia Pouzol, Sylvia Richard-Bildstein, Shuguang Yuan
  • Patent number: 10752620
    Abstract: The present invention relates to piperidine derivatives of formula (I) wherein Ar1, Ar2, RAr1, R1, R2 and R3 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: August 25, 2020
    Assignee: IDORSIA PHARMACEUTICALS LTD.
    Inventors: Hamed Aissaoui, Philippe Guerry, Francois Lehembre, Julien Pothier, Laetitia Pouzol, Sylvia Richard-Bildstein, Shuguang Yuan
  • Patent number: 10202368
    Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, ring (A), Y1, Y2, X, R4, L1, L2, and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: February 12, 2019
    Assignee: IDORSIA PHARMACEUTICALS LTD.
    Inventors: Philippe Guerry, Francois Lehembre, Julien Pothier, Hervé Siendt
  • Patent number: 9920010
    Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, R2a, R2b, R3a, R3b, R4, L1, L2, X, Y and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: March 20, 2018
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Heinz Fretz, Philippe Guerry, Thierry Kimmerlin, Francois Lehembre, Julien Pothier, Hervé Siendt, Anja Valdenaire
  • Patent number: 9428456
    Abstract: The present invention relates to 1-[m-carboxamido(hetero)aryl-methyl]-heterocycyl-carboxamide compounds of formula (I) wherein X, Ar1, R1, R2, R3, R4, R5a, R5b and p are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: August 30, 2016
    Assignee: ACTELION PHARMACEUTICALS LTD
    Inventors: Heinz Fretz, Markus Gude, Philippe Guerry, Thierry Kimmerlin, Francois Lehembre, Thomas Pfeifer, Anja Valdenaire
  • Publication number: 20130345199
    Abstract: The present invention relates to 1-[m-Carboxamido(hetero)aryl-methyl]-piperidine-4-carboxamide derivatives of formula (I) wherein X, Ar1, R1, R2, R3, R4, R5 and p are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Application
    Filed: June 21, 2013
    Publication date: December 26, 2013
    Applicant: Actelion Pharmaceuticals Ltd.
    Inventors: Heinz FRETZ, Markus Gude, Philippe Guerry, Thierry Kimmerlin, Francois Lehembre, Thomas Pfeifer, Anja Valdenaire
  • Patent number: 7524823
    Abstract: The present invention relates to new antibiotic macrolide compounds of the general formula I: with improved activity, to medicaments comprising such antibiotics, and to the use of such antibiotics for the treatment of infectious diseases, inflammatory diseases and human diseases or disorders which can be ameliorated by inhibition human phospdiesterases.
    Type: Grant
    Filed: May 8, 2006
    Date of Patent: April 28, 2009
    Assignee: Basilea Pharmaceutica AG
    Inventors: Johannes Laurenz Kellenberger, Stuart Robert Shapiro, Salima Mathews, Philippe Guerry, Pierre Jacques Noël Barbier
  • Patent number: 7265125
    Abstract: Quinoline and quinazoline derivatives can be used in the form of pharmaceutical preparations as Neuropeptide Y antagonists for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.
    Type: Grant
    Filed: April 7, 2005
    Date of Patent: September 4, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Volker Breu, Frank Dautzenberg, Philippe Guerry, Matthias Heinrich Nettekoven, Philippe Pflieger
  • Publication number: 20060264387
    Abstract: The present invention relates to new antibiotic macrolide compounds of the general formula I: with improved activity, to medicaments comprising such antibiotics, and to the use of such antibiotics for the treatment of infectious diseases, inflammatory diseases and human diseases or disorders which can be ameliorated by inhibition human phospdiesterases.
    Type: Application
    Filed: May 8, 2006
    Publication date: November 23, 2006
    Inventors: Johannes Kellenberger, Stuart Shapiro, Salima Mathews, Philippe Guerry, Pierre Noel Barbier
  • Patent number: 6995143
    Abstract: The invention provides new macrolides antibiotics of formula I with improved biological properties and having the formula wherein R1, R2 and R3 are as herein described.
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: February 7, 2006
    Assignee: Basilea Pharmaceutica AG
    Inventors: Philippe Guerry, Johannes Laurenz Kellenberger, Stéphanie Blanchard
  • Publication number: 20050176698
    Abstract: Quinoline and quinazoline derivatives can be used in the form of pharmaceutical preparations as Neuropeptide Y antagonists for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.
    Type: Application
    Filed: April 7, 2005
    Publication date: August 11, 2005
    Inventors: Volker Breu, Frank Dautzenberg, Philippe Guerry, Matthias Nettekoven, Philippe Pflieger
  • Patent number: 6900226
    Abstract: Quinoline and quinazoline derivatives can be used in the form of pharmaceutical preparations as Neuropeptide Y antagonists for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.
    Type: Grant
    Filed: August 27, 2001
    Date of Patent: May 31, 2005
    Assignee: Hoffman-La Roche Inc.
    Inventors: Volker Breu, Frank Dautzenberg, Philippe Guerry, Matthias Heinrich Nettekoven, Philippe Pflieger
  • Patent number: 6821980
    Abstract: The invention relates to substituted 5-benzyl-2,4-diaminopyrimidines of general formula (A) wherein R1 is C2-C3 alkyl an R2 is heterocyclyl, phenyl or naphthyl, bonded by one of its C-atoms and R3 is C2-C6 alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocyclylalkyl, alkylsulfonyl, cycloalkylsulfonyl, cycloalkylalkylsulfamoyl, heterocyclysylfonyl, heterocyclylalkylsulfonyl or dialkylsulfamoyl; wherein alkyl, cycloalkyl and alyenyl can carry up to 6 carbon atoms alone or in compositions and can carry up to 6 ring members heterocyclically, alone, or in compositions and the groups R2 and R3 can be substituted; and to acid addition salts of compounds. The invention also relates to a method for producing the above 5-benzyl-2,4-diaminopyrimidines, to the intermediate. products that are produced, to corresponding medicaments and to the use of 5-benzyl-2,4-diaminopyrimidines as medicinal preparations.
    Type: Grant
    Filed: July 18, 2002
    Date of Patent: November 23, 2004
    Assignee: Basilea Pharmaceutica AG
    Inventors: Philippe Guerry, Peter Mohr, Marc Muller, Werner Mueller, Philippe Pflieger
  • Publication number: 20030212011
    Abstract: The invention provides new macrolides antibiotics of formula I with improved biological properties and having the formula 1
    Type: Application
    Filed: February 20, 2003
    Publication date: November 13, 2003
    Inventors: Philippe Guerry, Johannes Laurenz Kellenberger
  • Publication number: 20020052356
    Abstract: Quinoline and quinazoline derivatives can be used in the form of pharmaceutical preparations as Neuropeptide Y antagonists for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.
    Type: Application
    Filed: August 27, 2001
    Publication date: May 2, 2002
    Inventors: Volker Breu, Frank Dautzenberg, Philippe Guerry, Matthias Heinrich Nettekoven, Philippe Pflieger
  • Patent number: 6114330
    Abstract: The invention is concerned with compounds of formula ##STR1## wherein R.sup.1 is lower-alkoxy, R.sup.2 is hydroxy or lower-alkoxy, R.sup.3 is hydrogen, cyano, alkyl, alkenyl, cycloalkyl, aryl, heterocycyl, aryl-Q-alkyl, or a group of the formula --CR.sup.4 R.sup.4 'COR.sup.5 --, Q is --SO-- or --SO.sub.2 --; R.sup.4, R.sup.4 ' are each independently hydrogen, alkyl, aryl or heterocyclyl, R.sup.5 is hydrogen, alkyl, alkoxy, hydroxy, aryl or heterocycyl, or R.sup.4 and R.sup.5 together form --(CH.sub.2).sub.n --, and n is a whole number between 2 to 5 inclusive and the enantiomers, epimers, and diastereomers thereof, as well as pharmaceutically acceptable salts thereof. These compounds have valuable antibacterial activity.
    Type: Grant
    Filed: February 25, 1998
    Date of Patent: September 5, 2000
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Philippe Guerry, Christian Hubschwerlen, Synese Jolidon, Jean-Luc Specklin, Pierre-Charles Wyss
  • Patent number: 5866583
    Abstract: Compounds of formula I ##STR1## wherein R.sup.1 is lower-alkoxy, R.sup.2 is bromine, lower-alkoxy or hydroxy, R.sup.3 is hydrogen, lower-alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl, heterocyclyl-lower-alkyl or cyano, R.sup.4 and R.sup.5 each independently are hydrogen, lower-alkyl, lower-alkoxy, halogen, hydroxy, amino, di(lower alkyl)amino, cyano or nitro and Q is ethynylene or vinylene, or pharmaceutically usable salts thereof, the use of these compounds and their salts as therapeutically active substances; medicaments based on these substances and their production; the use of these substances as medicaments and for the production of antibacterially-active medicaments; as well as the manufacture of the compounds of formula I and their pharmaceutically acceptable salts and intermediates for their manufacture.
    Type: Grant
    Filed: April 24, 1997
    Date of Patent: February 2, 1999
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Philippe Guerry, Henri Stalder, Pierre-Charles Wyss
  • Patent number: 5763450
    Abstract: Compounds of the formula: ##STR1## in which R.sup.1 is lower alkoxy, R.sup.2 is bromine or lower alkoxy, and R.sup.3 is aryl, heteroaryl or a group --Q--R.sup.30, wherein Q is ethylene, vinylene or ethynylene and R.sup.30 is aryl, heteroaryl, lower alkoxycarbonyl or carbamoyl;hydrolyzable esters of carboxylic acids of formula I; and pharmaceutically acceptable salts of these compounds are useful for treating infectious diseases.
    Type: Grant
    Filed: May 21, 1997
    Date of Patent: June 9, 1998
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Philippe Guerry, Synese Jolidon, Raffaello Masciadri, Henri Stalder, Rudolf Then
  • Patent number: 5239084
    Abstract: Antimycotically-active compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2 each independently are hydrogen, C.sub.1-7 -alkyl or C.sub.2-7 -alkenyl or together are a straight chain C.sub.2-4 -alkylene; R.sup.3 and R.sup.4 each independently are hydrogen or C.sub.1-7 -alkyl; R.sup.5 and R.sup.6 each independently are hydrogen, halogen, trifluoromethyl, nitro, cyano, C.sub.1-7 -alkoxy or C.sub.1-7 -alkyl; and Q is an unsubstituted or substituted phenyl or naphthyl group, wherein the substituents are at least one of halogen, trifluoromethyl, cyano, nitro, C.sub.1-7 -alkyl, C.sub.1-7 -alkoxy; C.sub.2-10 -alkenyl; or a substituted or unsubstituted C.sub.1-10 -alkyl group wherein said substituents are at least one hydroxy group; andpharmaceutically acceptable acid addition salts thereof.
    Type: Grant
    Filed: September 10, 1992
    Date of Patent: August 24, 1993
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Philippe Guerry, Synese Jolidon